Date: Saturday, June 2, 2018
Session Name: Poster Session A: Kidney: Cardiovascular and Metabolic
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Objective: There is a lack of high-level evidence identifying meaningful outcomes with direct oral anticoagulants (DOACs) in kidney transplant recipients. The primary objective of this study was to evaluate outcomes resulting from DOAC use in kidney transplant recipients.
Methods: In this single-center retrospective chart review, we evaluated adult kidney transplant recipients receiving DOAC therapy for cerebrovascular accident prophylaxis in non-valvular atrial fibrillation, or venous thromboembolism prophylaxis or treatment from January 1, 2011 to August 31, 2016. The primary outcome assessed the incidence of major bleeding events defined as a decrease in hemoglobin (Hgb) by at least 2 g/dl, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ during DOAC therapy.
Results: According to our predefined inclusion criteria, 62 patients were included in the study. Fourteen patients (22.6%) experienced a major bleed during DOAC therapy for a median follow-up of 8.7 months, leading to therapy discontinuation in 7 patients. There was no statistical difference in the incidence of major bleeding events between patients identified as receiving the appropriate DOAC dose versus those who did not receive appropriate dosing (19.4% vs. 3.2%, p = 1.00). Similarly, there was no difference in the incidence of major bleeding between patients with identified drug-drug interactions and those without drug-drug interactions (3.2% vs. 11.3%, p = 1.00).
|Table 1. Safety and Efficacy Outcomes||Overall (N=62)|
|Major bleeding event|
Reduciton in Hgb of at least 2 g/dl
Transfusion of at least 2 units of blood
Symptomatic bleeding in critical area/organ
|DOAC associated with major bleeding event|
|Minor bleeding event||9 (14.5%)|
|Discontinued DOAC therapy||7 (11.3%)|
|Hgb: hemoglobin; VTE: venous thromboembolism; DOAC: direct oral anticoagulant|
All data are presented in n (%).
Conclusions: DOAC therapy was not well tolerated in this cohort of kidney transplant recipients with respect to safety.
CITATION INFORMATION: Shaikh S., Samaniego M., Park J. Direct Oral Anticoagulation Use in Kidney Transplant Recipients Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Shaikh S, Samaniego M, Park J. Direct Oral Anticoagulation Use in Kidney Transplant Recipients [abstract]. https://atcmeetingabstracts.com/abstract/direct-oral-anticoagulation-use-in-kidney-transplant-recipients/. Accessed April 7, 2020.
« Back to 2018 American Transplant Congress